Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects

NCT03629873 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse
Mantle Cell Lymphoma
Peripheral T Cell Lymphoma
Double-hit Lymphoma

Interventions

DRUG: Chidamide

Sponsor

The First Affiliated Hospital with Nanjing Medical University